Galderma’s drug inhibits the signaling of a protein called IL-31, which is known to drive itch and is involved in inflammation, while drugs developed by competitors target a different protein.

a common type of eczema that causes itchy skin. Galderma filed applications for both indications with the U.S. Food and Drug Administration and the European Medicines Agency, and expects to launch ...

Galderma (SWX:GALD) today announced that the ... in which Nemluvio significantly improved itch, skin lesions and sleep disturbance, in patients with moderate-to-severe atopic dermatitis and ...

which causes intense itch and thick skin nodules, affects approximately 18,000 people in the UK. Despite available treatments, Galderma said there is a need for new options to effectively relieve the ...

Dermatology specialist Galderma has FDA approval for prurigo ... disease that causes hard lumps to form on the skin that are so itchy they can lead patients to scratch themselves to the point ...

On Sunday, March 9, Galderma will also host an Industry Session Theatre titled ‘Targeting the IL-31 Neuroimmune Pathway: Transforming Itch and Inflammation Outcomes’. Presented by Dr. Jonathan ...

which drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis, and fibrosis in prurigo nodularis 5,8-10 Nemluvio is the first ...